Skip to content

Chapters ENES DE

02Neoplasms
Neoplasms of haematopoietic or lymphoid tissues
Myeloproliferative neoplasms

2A20 category

Non mast cell myeloproliferative neoplasms

8 subordinate codes

2A20.0Chronic myelogenous leukaemia, BCR-ABL1-positive
2A20.1Chronic neutrophilic leukaemia
2A20.2Primary myelofibrosis
2A20.3Chronic eosinophilic leukaemia, not elsewhere classified
2A20.4Polycythaemia vera
2A20.5Non mast cell myeloproliferative neoplasm, unclassifiable
4B4YOther specified diseases of the immune system
4B4ZDiseases of the immune system, unspecified

Nearby in Myeloproliferative neoplasms

2A21Mastocytosis
4B4YOther specified diseases of the immune system
4B4ZDiseases of the immune system, unspecified

Next2A21 — Mastocytosis

Browse ICD-11

01Certain infectious or parasitic diseases
02Neoplasms
03Diseases of the blood or blood-forming organs
04Diseases of the immune system
05Endocrine, nutritional or metabolic diseases
06Mental, behavioural or neurodevelopmental disorders
07Sleep-wake disorders
08Diseases of the nervous system
09Diseases of the visual system
10Diseases of the ear or mastoid process
11Diseases of the circulatory system
12Diseases of the respiratory system
13Diseases of the digestive system
14Diseases of the skin
15Diseases of the musculoskeletal system or connective tissue
16Diseases of the genitourinary system
17Conditions related to sexual health
18Pregnancy, childbirth or the puerperium
19Certain conditions originating in the perinatal period
20Developmental anomalies
21Symptoms, signs or clinical findings, not elsewhere classified
22Injury, poisoning or certain other consequences of external causes
23External causes of morbidity or mortality
24Factors influencing health status or contact with health services
25Codes for special purposes
26Supplementary Chapter Traditional Medicine Conditions
VSupplementary section for functioning assessment
XExtension Codes
2A00-2A0ZNeoplasms of central nervous system or related structures
2A20-2B3ZNeoplasms of haematopoietic or lymphoid tissues
2B50-2E2ZMalignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
2E60-2E6ZIn situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
2E80-2F3ZBenign neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
2F70-2F7ZNeoplasms of uncertain behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues
2F90-2F9ZNeoplasms of unknown behaviour, except of lymphoid, haematopoietic, central nervous system or related tissues
Inherited cancer-predisposing syndromes
2A20-2A2ZMyeloproliferative neoplasms
2A30-2A3ZMyelodysplastic syndromes
2A40-2A4ZMyelodysplastic and myeloproliferative neoplasms
2A50-2A5ZMyeloid or lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1
2A60Acute myeloid leukaemias and related precursor neoplasms
2A61Acute leukaemias of ambiguous lineage
2A70-2A7ZPrecursor lymphoid neoplasms
2A80-2A8ZMature B-cell neoplasms
2A90-2B2ZMature T-cell or NK-cell neoplasms
5 more
2A20Non mast cell myeloproliferative neoplasms
2A21Mastocytosis
4B4YOther specified diseases of the immune system
4B4ZDiseases of the immune system, unspecified
2A20.0Chronic myelogenous leukaemia, BCR-ABL1-positive
2A20.1Chronic neutrophilic leukaemia
2A20.2Primary myelofibrosis
2A20.3Chronic eosinophilic leukaemia, not elsewhere classified
2A20.4Polycythaemia vera
2A20.5Non mast cell myeloproliferative neoplasm, unclassifiable
4B4YOther specified diseases of the immune system
4B4ZDiseases of the immune system, unspecified

International Classification of Diseases, Eleventh Revision (ICD-11), World Health Organization (WHO) 2019/2021, https://icd.who.int/browse11. Licensed under Creative Commons Attribution-NoDerivatives 3.0 IGO (CC BY-ND 3.0 IGO).

Release 2026-01. View this entity in the official WHO ICD-11 browser.

This page reproduces WHO classification content for reference. It is not medical advice and must not be used to diagnose or treat. For coding decisions, consult the official release and your national coding guidelines.

About · Data & methodology · Privacy · Contact